Page 96 - GTM-3-4

Global Translational Medicine Blood parameters for SCLC and AC relapse prognosis

predict the development of the tumor recurrence but also the Biomedical Ethics Committee of the educational
to evaluate the effectiveness of the therapy. institution “Belarusian State Medical University” (protocol
of the Committee meeting №2 dated 10/04/2021).
5. Conclusion

A regression equation has been developed to predict Consent for publication
the probability of tumor recurrence in patients with Not applicable.
Stage III SCLC based on measurements of CYFRA 21-1
concentration, the proportion of lymphocytes expressing Availability of data
the CXCR1 receptor, and blood monocytes expressing the Data used in this work can be made available to the readers
CXCR2 receptor in the pre-operative period. If the result by contacting the corresponding author.
of the equation exceeds 0.417, the risk of relapse is high,
and additional treatment measures are required to reduce References
it. The model’s PPV is 90.4%, NPV is 84.9%, sensitivity is 1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics.
84.9%, and specificity is 89.0%. Meanwhile, for the patients CA Cancer J Clin. 2023;73(1):17-48.
with Stage III AC, a different set of laboratory parameters
(CYFRA 21-1 level, lymphocytes expressing the CXCR1 doi: 10.3322/caac.21763
receptor, and the E/M ratio) can be incorporated into the 2. Araghi M, Mannani R, Heidarnejad MA, et al. Recent
logistic equation to improve the prognosis of relapse-free advances in non-small cell lung cancer targeted therapy; an
survival. If the result exceeds 0.597, the risk of relapse after update review. Cancer Cell Int. 2023;23(1):162.
the treatment is high. The model’s PPV is 89.6%, NPV is doi: 10.1186/s12935-023-02990-y
84.4%, sensitivity is 85.7%, and specificity is 94.8%.
3. Lababede O, Meziane MA. The eighth edition of TNM
Acknowledgments staging of lung cancer: Reference chart and diagrams.
Oncologist. 2018;23(7):844-848.
We appreciate Professor Victor T. Malkevich, the head of the doi: 10.1634/theoncologist.2017-0659
Laboratory of Thoracic Oncopathology at N.N. Alexandrov
National Cancer Center of Belarus, for his kind and fruitful 4. Wu G, Pan B, Shi H, et al. Neutrophils’ dual role in cancer:
cooperation and discussion on the study design. From tumor progression to immunotherapeutic potential.
Int Immunopharmacol. 2024;140:112788.
Funding doi: 10.1016/j.intimp.2024.112788
The work was carried out with financial support from 5. Carvalho S, Troost EG, Bons J, Menheere P, Lambin P,
the Ministry of Health of the Republic of Belarus, grant Oberije C. Prognostic value of blood-biomarkers related
2.17/20220385. to hypoxia, inflammation, immune response and tumour
load in non-small cell lung cancer - a survival model with
Conflict of interest external validation. Radiother Oncol. 2016;119(3):487-494.
The authors declare that they have no competing interests. doi: 10.1016/j.radonc.2016.04.024
6. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2
Author contributions axis in cancer and inflammatory diseases. Theranostics.
Conceptualization: Anatoli D. Tahanovich, Mikalai M. 2017;7(6):1543-1588.
Kauhanka doi: 10.7150/thno.15625
Investigation: Anatoli D. Tahanovich, Mikalai M. Kauhanka, 7. Wu K, Yu S, Liu Q, Bai X, Zheng X, Wu K. The clinical
Alexander V. Kolb, Oxana V. Gotko significance of CXCL5 in non-small cell lung cancer. Onco
Methodology: Anatoli D. Tahanovich, Mikalai M. Targets Ther. 2017;10:5561-5573.
Kauhanka, Violetta I. Prokhorova
Writing–original draft: Anatoli D. Tahanovich, Mikalai M. doi: 10.2147/OTT.S148772
Kauhanka, Violetta I. Prokhorova 8. Tahanovich AD, Kauhanka NN, Prohorova VI,
Writing–review & editing: Anatoli D. Tahanovich, Mikalai Murashka DI, Gotko OV. Determination of the risk of tumor
M. Kauhanka progression in patients with early stages of adenocarcinoma
and squamous cell lung carcinoma based on laboratory
Ethics approval and consent to participate parameters. Biochem Moscow Suppl Ser B. 2022;16:154-163.

All patients gave written voluntary consent to participate doi: 10.1134/S1990750822020081
in the study. The study was approved by the decision of 9. Tahanovich AD, Kauhanka NN, Kolb AV, et al. Prediction of

Volume 3 Issue 4 (2024) 12 doi: 10.36922/gtm.4865